Who We Are
Forging new paths with a shared vision
The core of Foamix is a hand-picked team of pharmaceutical industry professionals from all over the world who have come together to push past the conventional thinking they encountered in more traditional corporate structures. Our team has long-standing research and development experience, paired with strong commercial experience. We have a combination of diverse perspectives and industry experience necessary to recognize where conventional approaches fall short, and we are passionate about developing new and unexpected solutions to improving patient care.
From its foundation as a technically focused company solving intractable challenges in topical formulation, Foamix is emerging as an entrepreneurial and technology-savvy company of independent thinkers who are dedicated to bringing previously unavailable products to doctors and patients in need of innovation.
Chief Executive Officer
David Domzalski has served as Chief Executive Officer since July 2017. Mr. Domzalski has been with Foamix since April 2014, and previously served as President of Foamix Pharmaceuticals Inc. (US subsidiary). He has 25 years of industry experience, previously holding positions as Vice President, Sales and Marketing, at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President, Sales and Marketing, at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Chief Financial Officer and Country Manager
Ilan Hadar has served as Chief Financial Officer since February 2014 and as Israel Country Manager since July 2017. Mr. Hadar has over 20 years of experience in executive financial positions, previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager, Accounting and Reporting, at the Israeli subsidiary of HP from 2007 to 2011, and, prior to that, as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a BA in business administration and economics, and an MBA from The Hebrew University of Jerusalem.
Chief Commercial Officer
Matt Wiley has served as Chief Commercial Officer since November 2018. Mr. Wiley brings over 20 years of commercial and brand leadership experience, previously holding positions as Vice President of Marketing and Business Unit Lead at Jazz Pharmaceuticals from 2012 to 2018, as Vice President of Marketing at Azur Pharma from 2007 to 2012, and, prior to Azur, holding positions of increasing responsibility in sales, sales training, and marketing with Guilford/MGI Pharma, Salix Pharmaceuticals, Cephalon, and Rhone-Poulenc Rorer. Mr. Wiley holds a BA in English from Syracuse University.
Dr. Iain Stuart
Chief Scientific Officer
Iain Stuart, PhD, has served as Chief Scientific Officer since January 2019. Dr. Stuart has been with Foamix since October 2016, and previously served as Senior Vice President of Research and Development. He has over 19 years of industry experience, previously holding various positions at LEO Pharma, Inc. from 2008 to 2016, including Director of Preclinical Development, Director of Clinical Operations, Vice President of Research and Development Project Management, and, most recently, as Vice President of Medical Strategy and Scientific Affairs. Prior to LEO Pharma, Dr. Stuart served as Senior Study Director at Inveresk Research (now Charles River), and as Project Manager, Pharmaceutical Development at Cyclacel, Inc. Dr. Stuart has a PhD and first-class honors BSc in chemistry from Glasgow Caledonian University, and was a postdoctoral fellow in medicinal chemistry at the University of Strathclyde.
General Counsel and Chief Legal Officer
Mutya Harsch has served as General Counsel and Chief Legal Officer since January 2019. Ms. Harsch has been with Foamix since January 2018, and previously served as General Counsel and Senior Vice President of Legal Affairs. She has over 19 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions, at Cooley LLP from 2015 to 2017, as a corporate lawyer at Davis Polk & Wardwell from 1999 to 2003 and 2005 to 2015, and as Assistant General Counsel at Warner Chilcott from 2003 to 2005. Ms. Harsch received her JD and BA from the University of California at Berkeley.
Senior Vice President, Global Human Resources
Ray Steitz has served as Senior Vice President of Global Human Resources since November 2018. Mr. Steitz has over 30 years of human resources experience, previously holding positions as Senior Vice President of Human Resources at Olam Americas Inc. from 2010 to 2018, as Global Vice President of Human Resources at Warner Chilcott from 2001 to 2010, and, prior to Warner Chilcott, holding various human resources leadership and generalist roles at Unilever. Mr. Steitz holds a BS in business from Rider University.
Dr. Russell Elliott
Senior Vice President, Pharmaceutical Development
Russell Elliott, PhD, has served as Senior Vice President of Pharmaceutical Development since January 2019. Dr. Elliott has been with Foamix since May 2016, and previously served as Vice President of Drug Development. He has over 25 years of industry experience, previously holding positions as Head of Skincare Technology at Lonza Inc. from 2015 to 2016, Head of Product Development at Stiefel (a GSK Company) from 2011 to 2014, Head of the Center of Excellence for Liquids, Cream and Ointments at GSK (UK) from 2007 to 2011, and Principal Scientist at Procter & Gamble from 1992 to 2007. He has filed more than 60 patent applications in the area of skincare formulation. Dr. Elliott has a PhD and MA from the University of Oxford, and is a Fellow of the Royal Society of Chemistry.
Vice President, Regulatory Affairs
Deepa Desai has served as Vice President of Regulatory Affairs since March 2019. Ms. Desai has over 25 years of industry experience, previously holding positions as Senior Director of Regulatory Affairs at DBV Technologies from 2018 to 2019, Director of Global Regulatory Affairs at Radius Health from 2015 to 2018, Director of Regulatory Affairs at Actavis (formerly Warner Chilcott) from 2003 to 2015, and various positions in Quality Management and Regulatory Affairs at Hoffman-La Roche from 1992 to 2003. Ms. Desai holds a BA, biological sciences from Rutgers University and MS, biological sciences with a minor in business administration from Seton Hall University.
Vice President, Intellectual Property
David Schuz has served as Vice President of Intellectual Property since August 2017. Mr. Schuz has led the intellectual property function at Foamix since July 2006. Mr. Schuz has 20 years of industry experience in the field of pharmaceuticals and biotechnology intellectual property, previously holding positions at Biotechnology General Israel Ltd and Savient Pharmaceuticals, Inc. from 1999 to 2006, including Vice President from 2003 to 2006. Mr. Schuz holds an LLM from the London School of Economics, a certificate in patent law from Queen Mary London University, an M Phil (biochemistry) and a diploma of pharmacology, both from Cambridge University, and a BSc (Hons) (chemistry) from Manchester University.
Vice President, Quality
Bonnie Pappacena has served as Vice President of Quality since September 2017. Ms. Pappacena has over 30 years of quality and compliance expertise spanning across good clinical practices (GCP), good laboratory practices (GLP), and good manufacturing practices (GMP) for clinical supplies and commercial product and good pharmacovigilance practices (GVP) regulations. Ms. Pappacena has worked primarily in the pharmaceutical industry, and her experience includes drug product as well as combination product development. Prior to Foamix, Ms. Pappacena served as Vice President, Quality at G&W Laboratories, from 2016 to 2017, Vice President, Quality at Turing Pharmaceuticals, from 2015 to 2016, and Vice President, Quality at Acorda Therapeutics, from 2009 to 2015. Ms. Pappacena also held positions of increasing quality responsibility at Schering Plough Research Institute and Lederle (Wyeth). Ms. Pappacena has a BS/BA in psychology/philosophy from the University of Scranton, and an MS in experimental psychology from Villanova University.
Stanley Hirsch, DPhil, has been a member of the company’s board of directors since 2005, and has served as Chairman of the board of Foamix since May 2016. Dr. Hirsch has 30 years of experience in executive positions across the healthcare, diagnostic, and agricultural/biotech industries. He has extensive executive and board level experience in public and private companies listed on both US and UK exchanges. Dr. Hirsch is currently Group CEO at FuturaGene Ltd, a leading agricultural biotechnology company, where he has held this position since 2007. Prior to this role, Dr. Hirsch was the CEO at CBD Technologies Ltd., the predecessor company to FuturaGene, from 1995 to 2007. Prior executive positions held by Dr. Hirsch include CEO at a diagnostics company GamidaGen, and General Manager at Portman Pharmaceuticals. Dr. Hirsch currently also serves as chairman of the board of directors of OWC Pharmaceutical Research Corporation (OWCP), and as a board director and member of the Scientific Advisory Board of Biological Industries, a privately held research products company focused on the stem cell industry. Dr. Hirsch holds a DPhil in cell biology and immunology from Oxford University, England.
Stanley Stern has been a member of the company’s board of directors and Chairman of the Audit Committee since September 2014. Mr. Stern has over 30 years of experience as an investment banker, holding positions at Salomon Brothers, C.E. Unterberg, STI Ventures, and from 1982 to 1999, and also from 2004 to 2013, at Oppenheimer & Co., serving as Managing Director and Head of Investment Banking, Head of Technology, Israeli Banking and Financial Institutions Groups (FIG). Since February 2013, Mr. Stern has served as President of Alnitak Capital Partners, a private merchant bank and strategic advisory firm. From 2002 to 2013, Mr. Stern served as a member of the board of directors of Tucows, Inc., a publicly traded internet service provider, including as Chairman of the board from 2002 to 2012. From 2005 to its sale in 2011, he served as a director at Fundtech Ltd, and from 2004 to 2009, Mr. Stern served as a director at Odimo Inc. (DBA Diamond.com), an online jewelry vendor. From 2012 to its sale in 2014, he served as a director at Given Imaging Ltd, a medical device company. Mr. Stern is currently Chairman of the board of directors of Soda Stream and AudioCodes Ltd. In addition, he serves on the board of directors of Ormat Technologies, Inc., Ekso Bionics and Tigo Energy, Inc. Mr. Stern holds an MBA from Harvard Business School and a BA from Queens College.
Rex Bright has been a member of the company’s board of directors and Chairman of the Compensation Committee since September 2014. Mr. Bright is a specialty pharmaceuticals and biotech executive with extensive experience in dermatology. Mr. Bright has spent over 20 years as a start-up and turnaround CEO, and most recently founded and served as President and CEO of SkinMedica until it was acquired by Allergan in 2012. Prior to SkinMedica, Mr. Bright was President of Allergan Skincare and spent 19 years at Johnson & Johnson leading their dermatology division, which included the launch of Retin-A. He served on the board of directors of RestorGenex, Inc. through the Company’s merger with Diffusion Pharmaceuticals in 2016. Mr. Bright currently is a member of the board of directors of Clarify Medical and MDRejuvenia. He completed executive programs at Harvard, Stanford, and Northwestern University, and holds a BA in business administration from Drury University in Springfield, Missouri.
Anna Kazanchyan, MD has been a member of the company’s board of directors since December 2014. She is a biotechnology executive with 20 years of experience at Wall Street firms, biopharmaceutical companies, and as an entrepreneur. Since September 2016, Dr. Kazanchyan has been the CEO and Chairwoman at Saghmos Therapeutics, a company which she founded that is focused on the prevention of contrast-induced acute kidney injury. She is also the founder and Managing Partner since 2004 of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceutical companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan has been an Executive Advisor to CEOs of biopharmaceutical companies (start-ups to global companies) on clinical development, regulatory, and commercial strategy, as well as business development and valuation. Previously, she was Senior Vice President, Business Development and Product Development at Ovid Therapeutics, a company focused on rare neurological disorders. Dr. Kazanchyan was also a Senior Biotechnology Analyst at Wachovia Securities, and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup. She currently serves on the board of directors of Innovate Biopharmaceuticals (Nasdaq: INNT). Dr. Kazanchyan received an MD from Harvard Medical School and a BA in biology, summa cum laude, from Clark University.
Tony Bruno has been a member of the company’s board of directors since November 2018. Mr. Bruno is a highly accomplished senior pharmaceutical executive with broad expertise in legal, business development, and corporate development functions within the industry, as well as significant experience in product licensing and M&A transactions. He has spent over 30 years in the pharmaceutical industry, most recently serving as a strategic advisor to Foamix from 2014 until 2018. He was employed at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President with responsibility for all business development activities including product acquisitions and divestitures as well as licensing agreements. Prior to this, he served as General Counsel for Warner Chilcott, where he was responsible for all legal activities. From 1984 to 2000, Mr. Bruno held several positions of increasing responsibility within Warner Lambert’s legal division, culminating as General Counsel to the company’s pharmaceutical business. Prior to working in the pharmaceutical industry, Mr. Bruno began his legal career as an associate with Shearman & Sterling in New York in 1981. He received a JD with honors from George Washington Law School, and graduated magna cum laude from Syracuse University with a BA in political science.
David Domzalski has been a member of the company’s board of directors since January 2018. Mr. Domzalski has served as our Chief Executive Officer since July 2017. Prior to his role as CEO, Mr. Domzalski served as the President of Foamix Pharmaceuticals Inc. (U.S. subsidiary) since joining the company in April 2014. He has 25 years of industry experience, previously holding positions as Vice President Sales and Marketing at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President Sales and Marketing at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Dr. Aaron Schwartz has been a member of the company’s board of directors since November 2014. He had a distinguished career at Teva Pharmaceuticals spanning nearly four decades, where he served in various senior executive positions until his retirement in 2011, with his most recent role being Vice President, Head of Teva Innovative Ventures. From January 2013 to November 2017, he served as a member of the board of directors of Alcobra Ltd. Dr. Schwartz is currently Chairman of the board of BiolineRx Ltd., and a member of the board of directors of Barcode Ltd. Dr. Schwartz received a PhD in organic chemistry from Weizmann Institute of Science, and a PhD in the history and philosophy of science from The Hebrew University of Jerusalem. He also received an MSc in organic chemistry from Technion, and a BSc in chemistry and physics from The Hebrew University of Jerusalem.
Sharon Barbari has been a member of the company’s board of directors since January 2019. Ms. Barbari has over 40 years of pharmaceutical and biotechnology experience. From 2004 to 2017, she was Chief Financial Officer at Cytokinetics. Ms. Barbari spent 4 years from 1998 to 2002 in senior financial roles at Gilead Sciences, including CFO. In this position, she led the finance, accounting, and information technology functions during a period of significant growth for Gilead. Ms. Barbari was also employed as CFO and Senior Vice President of Finance and Administration at InterMune, and Vice President of Strategic Planning at Foote, Cone & Belding Healthcare. She began her career at Syntex Corporation/Roche Pharmaceuticals, where she held various roles of increasing responsibility from 1972 to 1996. Ms. Barbari currently serves as a board member for Sonoma Pharmaceuticals, and as a board member for the Association of Bioscience Finance Officers. She previously was a board member for Phytogen Life Sciences. In 2017, Ms. Barbari was a recipient of the YWCA Silicon Valley Tribute to Women Awards. She received her BS in accounting from San Jose State University.